Professional Documents
Culture Documents
BONE LOSS
Since you can't see or feel bone loss, it can happen without you knowing, increasing your risk of fracture. After menopause, taking calcium supplements is important, but alone may not be enough to prevent fractures caused by osteoporosis.
Cancellous bone
cancellous bone, also called trabecular bone or spongy bone, light, porous bone enclosing numerous large spaces that give a honeycombed or spongy appearance. The bone matrix, or framework, is organized into a three-dimensional latticework of bony processes, called trabeculae, arranged along lines of stress. The spaces between are often filled with marrow
Compact Bone
compact bone, also called cortical bone, dense bone in which the bony matrix is solidly filled with organic ground substance and inorganic salts, leaving only tiny spaces (lacunae) that contain the osteocytes, or bone cells. Compact bone makes up 80 percent of the human skeleton; the remainder is cancellous bone, which has a spongelike appearance with numerous large spaces and is found in the marrow space (medullary cavity) of a bone. Both types are found in most bones. Compact bone forms a shell around cancellous bone and is the primary component of the long bones of the arm and leg
Osteocytes, osteoblasts
Osteoblasts are mononucleate cells that are responsible for bone formation. osteoblasts are specialized fibroblasts. Osteoblasts produce a matrix of osteoid, which is composed mainly of Type I collagen. Osteoblasts are also responsible for mineralization of this matrix. Bone is a dynamic tissue that is constantly being reshaped by osteoblasts, in charge of production of matrix and mineral, and osteoclasts, which remodel the tissue. Osteoblast cells tend to decrease with age, affecting the balance of formation and resorption in the bone tissue
Fibroblasts
A fibroblast is a type of cell that synthesizes the extracellular matrix and collagen,[1] the structural framework (stroma) for animal tissues, and plays a critical role in wound healing
Osteoclasts
An osteoclast is a type of bone cell that removes bone tissue by removing its mineralized matrix and breaking up the organic bone (organic dry weight is 90% collagen). This process is known as bone resorption.
Osteoporosis
Normal Bone
Osteoporotic Bone
Normal Bone
Moderate Osteoporosis
Severe Osteoporosis
OSFIT
OSFIT
OSFIT
Treatment
Follow-up
Pharmacotherapy
(antiresorptives and anabolics)
Lifestyle Changes Pyramid for Osteoporosis Prevention and Treatment (nutrition, physical activity, and fall prevention)
1,500,000
1.5
1.0
0.5
250,000
345,000
Fracture1
Hip fracture1
Heart attack2
Breast cancer3
Risk of osteoporotic fracture in 1 year is greater than combined risk of heart attack, stroke, and breast cancer.
1. Riggs BL, Melton LJ III. Bone. 1995;17(suppl):505S511S. 2. American Stroke Association. Heart disease and stroke statistics2005 update. Available at: http://www.americanheart.org. Accessed August 24, 2005. 3. American Cancer Society. Cancer facts & figures; 2005. Available at: http://www.cancer.org. Accessed August 24, 2005.
Osteoporosis
Osteoporosis is defined as a skeletal disorder characterized by compromised bone strength predisposing to an increased risk of fracture. NIH Consensus Development Conference, March 2000
Normal Bone
Osteoporotic Bone
Central Devices
Central DXA
Measures bone density at the hip and spine
Women age 65 and older Men age 70 and older Women and men over 50 with risk factors Patients with a fracture after age 50
Lifestyle Changes Pyramid for Osteoporosis Prevention and Treatment (nutrition, physical activity, and fall prevention)
Lifestyle Issues
Tobacco- eliminate it Alcohol moderate it Food eat it Exercise do it Fall Prevention work on it
Lifestyle Issues
Tobacco - eliminate it Alcohol moderate it Nutrition - adequate weight, protein-magnesium, trace elements....multivite Exercise strength, aerobic, flexibility, balance Fall prevention- home safety, shoes, walking aids, glasses
Nutrition
Appropriate Body Weight
BMI 22 - 25
Adequate nutrition
Protein
Multi-vitamin daily
C, D, K, Copper, Manganese, Zinc, Phosphorus
Nutritional supplements
Ensure, Boost
Nutrition
Milk, Yogurt
Calcium, magnesium, potassium, phosphorus, zinc, protein, vitamin A, vitamin D, vitamin B12, riboflavin
Risk reduction for
Osteoporosis, hypertension, obesity, colon cancer, diabetes, metabolic syndrome
Exercise
Walking reduces hip fracture risk
4 hours per week reduced hip fracture by 41% in a study of 61,200 women
JAMA 2002
Falling
Medications, Alcohol Balance programs Strength training Safety at home Hip protectors Walking aids
Vitamin D 800-2000 IU ?
Vitamin D is important for good bone health because it aids in the absorption and utilization of calcium. There is a high prevalence of Vitamin D deficiency in nursing home residents, hospitalized patients, and adults with hip fractures. ..and many others
Surgeon Generals Report on Bone Health 2004
Vitamin D
Sufficiency > 32 ng/ml Comfort zone- 40s, 50s
Many wellness relationships
Vitamin D
Improves calcium absorption Direct action on building bone matrix Decreases FALLS Increases muscle mass and strength Etc etc................
Lifestyle Changes Pyramid for Osteoporosis Prevention and Treatment (nutrition, physical activity, and fall prevention)
Frailty Factor
Acute Medical Illnesses Chronic Medical Illnesses
Sarcopenia
(degenerative loss of skeletal muscle mass and strength associated with aging)
Falling
Medication Check
Corticosteroids Anticonvulsants PPIs SSRIs
Lifestyle Changes Pyramid for Osteoporosis Prevention and Treatment (nutrition, physical activity, and fall prevention)
Pharmacotherapy
(Medications)
Medications
Prevent and Treat Thresholds
1. The Fracture Patient or < or = -2.5 T score 2. Bone density = or < - 2.0 3. Bone density = or < -1.5 with risk factors Guidelines for post menopausal women And men over 50
FRAX
www.nof.org/professionals/Clinicians_Guide.htm
http://www.shef.ac.uk/FRAX
NOF - National Osteoporosis Foundation FRAX - WHO Fracture Risk Assessment Tool
Fragility fracture- hip or spine T-score -2.5 T-score -1.0 to -2.5 (osteopenia) and
10-year all major osteoporosis-related fracture probability of 20% or a 10-year hip fracture probability 3% (FRAX)
www.nof.org
Pharmacotherapy
(antiresorptives and anabolics)
Lifestyle Changes
(nutrition, physical activity, and fall prevention)
Anti-Resorptives (Anti-Catabolics)
Bisphosphonates
Estrogens (HRT) SERMs
Raloxifene
Calcitonin
Osteoporosis T-score -2.5 or less at FN or LS after evaluation for secondary causes, or Hip or vertebral (clinical or morphometric) fracture
Osteopenia T-score between -1.0 and -2.5 at FN or LS, and FRAX 10-year probability of major osteoporotic fracture 20% or hip fracture 3%
National Osteoporosis Foundation. Clinicians Guide to Prevention and Treatment of Osteoporosis. 2008.
Osteoporosis:
A disease characterized by low bone mass and deterioration of bone structure that causes bone fragility and increases the risk of fracture1
1US
Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004.
54
Medication-Taking Behaviors
Most common types of non-adherence
Not having prescription filled Taking incorrect dose Taking dose at the wrong time Forgetting one or more doses Stopping medication too soon
Always
Never
Sometimes
Patients who are nonadherent visit physicians 3 times as often as comparable patients
American Pharmaceutical Association. Medical compliance, adherence and persistence (CAP) digest. APhA: Washington, DC 2003.
55
BALTO I
BONIVA, ALendronate Trial in Osteoporosis
Patient preference study
Once-monthly dosing of Ibandronate vs Once-weekly dosing of Alendronate
56
Primary objective: - Evaluate patient-reported preference for either once-monthly dosing of Ibandronate (BONIVA) or once-weekly dosing of alendronate Secondary objective: - Assess convenience of once-monthly dosing of Ibandronate (BONIVA) vs once-weekly dosing of alendronate BMD increases and fracture reductions were not assessed
26.5% (n=79)
66.1%* (n=197)
Most common reasons given for patient preference were: Ease of following a treatment dosing regimen for a long time Dosing regimen fits patients lifestyle better
* p<.0001 Preference expressed 1 treatment dosing regimen over the other (modified ITT) population Emkey R, et al. Curr Med Res Opin. 2005;21:1895-1903.
10.8% (n=32)
22.6% (n=67)
66.6%* (n=197)
* p<.0001 Preference expressed 1 treatment dosing regimen over the other (modified ITT) population Emkey R, et al. Curr Med Res Opin. 2005;21:1895-1903.
BALTO I Conclusions
A significantly greater percentage of patients preferred once-monthly Ibandronate (BONIVA) dosing to once-weekly alendronate dosing and found the once-monthly regimen to be more convenient Most common reasons given for patient preference were: The ease of following a treatment dosing regimen for a long time Dosing schedule fitting better into the patients lifestyle These results were confirmed in a second replicate study, BALTO II
IBANDRONATE SODIUM
A Bisphosphonate
Indications
Ibandronate is indicated for the treatment and prevention of osteoporosis in postmenopausal women In postmenopausal women with osteoporosis, Ibandronate increases BMD and reduces the incidence of vertebral fractures Ibandronate may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of fracture
Bisphosphonates
Adverse events
GI (same as placebo in studies) Flu-like Acute Phase Reaction Bone pain Hypocalcemia Iritis/Uveitis ONJ - Osteonecrosis of the jaw Unusual subtrochanteric fractures
Comparative Risks
Any Fragility Fracture (1) Hip Fracture (1) Anaphylaxis from PCN Shot Death by MVA Death by Murder ONJ- Osteoporosis Patient Death by Lighting Strike in NM
0
(1) Women age 65-69 (from Swedish National Bureau of Statistics and database of Olmsted County, MN, USA.)
Kanis JA et al. Osteoporos Int. 2001;12:417-427. Pharmcoepidemiol Drug Saf. 2003;12:195202. National Center for Health Statistics. JADA. 2006;137:1144-1150. www.nssl.noaa.gov/papers/techmemos/NWS-SR-193/techmemo-sr193-4.html
Contraindications
Ibandronate is contraindicated in patients
Who are unable to stand or sit upright for at least 60 minutes With uncorrected hypocalcemia With known hypersensitivity to Ibandronate or any of its excipients
65
Warnings
Ibandronate, like other bisphosphonates
administered orally, may cause upper gastrointestinal disorders such as dysphagia, esophagitis, and esophageal or gastric ulcer Patients should be advised to comply with dosing instructions to minimize the risk of these effects
Precautions
Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting therapy Adequate intake of calcium and vitamin D is important in all patients
Drug Interactions
Ibandronate do not undergo hepatic metabolism and do not inhibit the hepatic cytochrome P450 system. Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate. Since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.
Conclusions on
Improving Medication Adherence
Conclusions
Adherence to osteoporosis medications is a significant problem only recently getting the attention it needs Poor adherence impacts short- and long-term health outcomes in patients with osteoporosis